Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

Polypeptides

Leuprolide Acetate 74381-53-6

Leuprolide Acetate 74381-53-6

97% up by HPLC, USP
  • Product Details

Product Information


Product name

Leuprolide Acetate

CAS No.

74381-53-6

Molecular Formula

C59H84N16O12

Molecular Weight

1269.65

Molecular Structure

Quality Standard

97% up by HPLC, USP

Appearance

White powder


COA of Leuprolide acetate


ITEMS

SPECIFICATION

RESULT

Appearance

White powder

Conforms

Solubility

Soluble in water or 1% acetic acid at a

concentration of ≥1mg/ml to give a clear,

colorless solution

Conforms

Identity

 IR

Same with the reference spectrum of Leuprolide

Conforms

HPLC

Same with the reference solution

Conforms

Amino Acid Analysis

Conforms

Ser: Present

Glu: 0.851.1

Pro: 0.851.1

Leu: 1.802.2

Tyr: 0.851.1

His: 0.851.1

Arg: 0.851.1

Trp: Present

Present

0.99

1.05

2.02

1.02

0.98

1.01

present

Specific Optical Rotation

-38.0-42.0° [a]20D(c=11% HAc)

-40.1°

RelatedSubstance

(By HPLC)

Total Impurities(%)≤2.5%

acetyl-leuprolide≤1.0%

D-His-leuprolide≤0.5%

L-Leu6-leuprolide≤0.5%

D-Ser-leuprolide≤0.5%

Any other Impurity≤0.5%

0.17%

Conforms

Conforms

Conforms

Conforms

0.17%

Acetate Content(By HPLC)

4.7~9.0%

7.5%

Water Content(Karl Fischer)

≤5.0%

1.5%

Sulphate ash

≤0.3%

Conforms

Bacterial Endotoxins

≤16.7 IU/mg

Conforms

Residual Organic Solvents

Acetonitrile ≤0.041%(By GC)

DMF ≤0.088%(By GC)

MEOH ≤0.3%(By GC)

TFA ≤0.1%(By HPLC)

Conforms

Conforms

Conforms

Conforms

Assay(By Anhydrous, Acetic Acid-free )

97.0103.0%

99.5%


Usage


Function of Leuprolide Acetate

Leuprolide is a gonadotropin drug, a villous solid, and is often used clinically for endometriosis; uterine fibroids accompanied by menorrhagia, lower abdominal pain, low back pain and anemia; premenopausal breast cancer, and Estrogen receptor-positive patients; prostate cancer; central precocious puberty.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
nonapeptide-1
Nonapeptide-1 158563-45-2
99% up by HPLC
Linaclotide
Linaclotide 851199-59-2
98% up, Medical Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact